Should Drug Prices Be Negotiated Under Part D Of Medicare? And If So, How?-Reference-Cited by-同舟云学术

Should Drug Prices Be Negotiated Under Part D Of Medicare? And If So, How?

Published:2008-01 Issue:1 Volume:27 Page:33-43
ISSN:0278-2715
Container-title:Health Affairs
language:en
Short-container-title:Health Affairs

Author:

Frank Richard G.,Newhouse Joseph P.

Publisher

Health Affairs (Project Hope)

Subject

Health Policy

Reference5 articles.

1. ; R.G. Frank , “Prescription Drug Prices: Why Do Some Pay More than Others Do?”Health Affairs20, no. 2 ( 2001 ): 115 –128

2. ; and J.P. Newhouse , “How Much Should Medicare Pay for Drugs?”Health Affairs23, no. 1 ( 2004 ): 89 –102.

3. The Strategic Response by Pharmaceutical Firms to the Medicaid Most- Favored-Customer Rules

4. Was Part D a Giveaway to the Pharmaceutical Industry?

5. For reviews of the empirical literature on final-offer arbitration, see O. Ashenfelter and J. Currie, “Negotiator Behavior and the Occurrence of Disputes,”American Economic Review80, no. 2 ( 1990 ): 416 –420

Cited by 50 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Trends of Negotiated Targeted Anticancer Medicines Use in China: An Interrupted Time Series Analysis;International Journal of Health Policy and Management;2021-06-09

2. How protected classes in Medicare Part D influence U.S. drug sales, utilization, and price;Health Economics;2020-05

3. Mergers in Medicare Part D: Assessing market power, cost efficiencies, and bargaining power;International Journal of Industrial Organization;2020-01

4. Value‐based pricing: Toward achieving a balance between individual and population gains in health benefits;Cancer Medicine;2019-11-11

5. U.S. Pharmaceutical Markets: Expenditures, Health Insurance, New Products and Generic Prescribing from 1960 to 2016;International Journal of the Economics of Business;2019-09-24